ETH Spinoff enters an agreement with Boehringer Ingelheim


InterAx Biotech has entered a partnership with the German pharma giant Boehringer Ingelheim to enable the in-depth characterization of drug candidates for an undisclosed target. The activity relies on the proprietary InterAx systems biology platform.


InterAx, a spinoff from the ETH Zürich and Paul Scherrer Institute, is pioneering computational pharmacology for drug discovery to assist drug candidate design and selection. InterAx applies mathematical models and simulations to in-house derived bioanalytical data in order to address the complexity of drug-induced cellular signalling mechanisms. Currently, the InterAx technology is applicable to all drug discovery programs on G protein-coupled receptors (GPCRs) in collaborative projects with Biotech and Pharma companies. Large pharma companies – such as Lundbeck A/S, specialized in psychiatric and neurological disorders – are already using the technology. Expanding on its partner portfolio, InterAX has signed a collaboration agreement with Boehringer to characterize drug candidates for an undisclosed target using InterAx systems biology platform. Financial terms of the partnership were not disclosed. “We are looking forward to combining our unique technology with the expertise of Boehringer Ingelheim to identify compounds with superior biological properties for one of Boehringer’s target receptors”, says Maria Waldhoer, CSO at InterAx.  (Press release)